藥明康德(02359.HK)擬配售7380萬股H股 總籌77億港元加速全球佈局
格隆匯7月31日丨藥明康德(02359.HK)發佈公告,2025年7月31日(交易時間前),公司與配售代理(即摩根士丹利、花旗、高盛及匯豐)訂立配售協議,據此,公司同意委任配售代理而配售代理各自同意(而非共同,亦非共同及個別)出任公司代理,並盡力促使承配人按照配售協議所載條款及條件,按每股配售股份配售價104.27港元合共認購7380萬股新H股。
配售股份數目分別佔:(a)截至本公告日期現有已發行H股總數及現有已發行股份總數約19.07%及2.57%;及(b)緊隨完成後經發行配售股份擴大後的已發行H股總數及已發行股份總數約16.01%及2.51%。配售股份將根據一般授權予以發行。配售毋須股東另行批準。公司將向香港聯交所上市委員會申請批準配售股份上市及買賣。
假設所有配售股份獲悉數認購,配售的募集資金總額預計將約爲77.0億港元。配售的募集資金淨額預計約爲76.5億港元,將按以下方式投入使用:(a)約90%將用於加速推進全球佈局和產能建設;及(b)約10%將用於一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.